Financials

  • Market Capitalization 9.03 B
  • Employee 423
  • Founded 1998
  • CEO Helen I. Torley
  • Website www.halozyme.com
  • Headquarter Delaware, United States
  • FIGI BBG000CZ8W54
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
22.68
Price to sales ratio
5.28

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
959
CORT
Corcept Therapeutics Incorporated - Common Stock
85.90 USD-6.51%-6.98%+3.61%+17.08%9.22 B USD
967
KYMR
Kymera Therapeutics, Inc. - Common Stock
110.40 USD-7.50%-4.18%+27.97%+86.80%9.08 B USD
983
CRNX
Crinetics Pharmaceuticals, Inc. - Common Stock
83.67 USD+0.11%+0.11%+141.96%+103.58%8.82 B USD
987
PRAX
Praxis Precision Medicines, Inc. - Common Stock
314.56 USD-3.21%-0.17%+16.12%+482.63%8.77 B USD

Frequently asked questions about Halozyme Therapeutics, Inc. - Common Stock

What is the Halozyme Therapeutics, Inc. - Common Stock stock price today?

The current price of Halozyme Therapeutics, Inc. - Common Stock (HALO) is 76.11. Over the past 24 hours, the stock has changed by -0.12%. Follow the HALO chart for real-time price dynamics.

What is the stock ticker of Halozyme Therapeutics, Inc. - Common Stock?

Halozyme Therapeutics, Inc. - Common Stock trades under the ticker HALO. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Halozyme Therapeutics, Inc. - Common Stock stock going up?

HALO has changed by -6.56% over the last week, +8.54% over the last month, and +13.94% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Halozyme Therapeutics, Inc. - Common Stock net income for the last quarter?

Halozyme Therapeutics, Inc. - Common Stock reported net income of 150.05 M for the last quarter. The previous quarter showed -141.59 M, which means net income changed by +205.97%.

How many employees does Halozyme Therapeutics, Inc. - Common Stock have?

As of the latest available data, Halozyme Therapeutics, Inc. - Common Stock has 423 employees. Workforce size can provide additional context about the company's scale and operations.

What is Halozyme Therapeutics, Inc. - Common Stock EBITDA?

Halozyme Therapeutics, Inc. - Common Stock EBITDA is 188.74 M, and its EBITDA margin is 50.1%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Halozyme Therapeutics, Inc. - Common Stock stock?

You can buy Halozyme Therapeutics, Inc. - Common Stock (HALO) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Halozyme Therapeutics, Inc. - Common Stock stock?

Investing in Halozyme Therapeutics, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the HALO chart and related analysis on metatrader.com as part of your research.

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

News